COVID vaccine: French drugmaker Sanofi halts development of its mRNA jab

Paying Social Media Jobs
Social sharing

French drugmaker Sanofi announced on Tuesday it is halting the development of one of its two COVID-19 vaccines.

The company said it will not proceed with Phase III for its messenger RNA vaccine despite positive interim results in the clinical trials.

Sanofi believes it will be too late in reaching the market.

Its other vaccine, based on a recombinant protein developed with Britain’s GlaxoSmithKline, is already undergoing Phase III trials with results expected before the end of the year.

According to the company, its mRNA vaccine triggers antibody production in 91% to 100% two weeks after a second injection. No side effects were observed and the tolerance profile was similar to the other mRNA COVID-19 vaccines already deployed from Pfizer/BioNTech and Moderna.

The jab had been developed in collaboration with Translate Bio, a US biotech company the French drugmaker acquired in August for €2.7 billion.

Thomas Triomphe, vice-president of Sanofi’s vaccines division, said the company had wanted to evaluate the mRNA technology’s capacity to generate an immune response.

Messenger RNA vaccines use inactivated viruses to trick the body into creating a protein that triggers a person’s immune system.

The technology has been studied for decades but its application is fairly recent. It allows for a fast development phase that scientists believe can be standardised and scaled up to respond to diseases for which there currently is no vaccine or to future outbreaks.

Sanofi’s Triomphe said the company’s decision to abandon its jab was because “the need is not to create new COVID-19 RNA vaccines but to equip France and Europe with an arsenal of messenger RNA vaccines for a future pandemic, for new diseases.”

READ ALSO  Polish region revokes anti-LGBT declaration over loss of EU funding

The group has already launched initial trials for a monovalent vaccine — with a single strain of the virus — against seasonal flu. On Tuesday it said it would launch clinical trials next year against influenza, this time with a quadrivalent vaccine.


About 9News Nigeria 8843 Articles
9News Nigeria is Nigeria's favourite news source.For Authentic, Unbiased News on Politics, Business, Sports, Technology, Entertainment and Lifestyles, Health, Nollywood, Crime and Investigations, Family and Relationships, Inspirations .. and much more.For Latest News from Africa and around the world, 9News Nigeria is your best source. WhatsApp +2348115805632 Email: Facebook: | Twitter/Instagram: @9newsng

Be the first to comment

Leave your comment

Paying Social Media Jobs
Paying Social Media Jobs
Paying Social Media Jobs